Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study
Obesity · 2024-03 · 32 (3) · 486-493
DOI: 10.1002/oby.23952 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Obesity, online erschienen am 06.12.2023. Verfasst von Hamlet Gasoyan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Objective
The study's objective was to examine the percentage of patients with an initial antiobesity medication (AOM) fill who were persistent with AOM at 3, 6, and 12 months and to characterize factors associated with persistence at 12 months.
Methods
This retrospective cohort study used electronic health records from January 2015 to July 2023 in a large health system in Ohio and Florida and included adults with BMI ≥30 kg/m 2 who had an initial AOM prescription filled between 2015 and 2022.
Results
The authors identified 1911 patients with a median baseline BMI of 38 (IQR, 34–44). Over time, 44% were persistent with AOM at 3 months, 33% at 6 months, and 19% at 12 months. Across categories of AOM, the highest 1‐year persistence was in patients receiving semaglutide (40%). Semaglutide (adjusted odds ratio [AOR] = 4.26, 95% CI: 3.04–6.05) was associated with higher odds of 1‐year persistence, and naltrexone‐bupropion (AOR = 0.68, 95% CI: 0.46–1.00) was associated with lower odds, compared with phentermine‐topiramate. Among patients who were persistent at 6 months, a 1% increase in weight loss at 6 months was associated with 6% increased odds of persistence at year 1 (AOR = 1.06, 95% CI: 1.03–1.09).
Conclusions
Later‐stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Hamlet Gasoyan
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., & Rothberg, M. B. (2024). Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study. Obesity, 32(3), 486-493. https://doi.org/10.1002/oby.23952
Vancouver
Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study. Obesity. 2024;32(3):486-493. doi:10.1002/oby.23952
BibTeX
@article{Gasoyan2024,
author = {Gasoyan, Hamlet and Pfoh, Elizabeth R and Schulte, Rebecca and Le, Phuc and Rothberg, Michael B},
title = {Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study},
journal = {Obesity},
year = {2024},
volume = {32},
number = {3},
pages = {486--493},
doi = {10.1002/oby.23952}
}
EUVIMED